Corporate news – Targovax

November 3, 2022

Press release - Regulatory

Targovax ASA: Third quarter 2022 results

October 26, 2022

Press release - Regulatory

Invitation to Targovax’s third quarter 2022 presentation, Thursday 3 November

August 18, 2022

Press release - Regulatory

Targovax ASA: Second quarter and first half year 2022 results

May 12, 2022

Press release - Regulatory

Targovax ASA: First quarter 2022 results

May 11, 2022

Press release - Regulatory

Targovax announces clinical collaboration with Agenus for upcoming ONCOS-102 phase 2 melanoma trial

March 30, 2022

Press release - Regulatory

Notice of Annual General Meeting

March 9, 2022

Press release - Regulatory

Targovax ASA: Annual Report 2021

February 28, 2022

Press release - Regulatory

Targovax ASA strengthens management with Lubor Gaal as Chief Financial Officer

February 17, 2022

Press release - Regulatory

Targovax ASA: Fourth quarter 2021 results

February 9, 2022

Press release - Regulatory

Targovax ASA: Invitation to presentation of Targovax’s fourth quarter 2021 results, Thursday 17 February

February 1, 2022

Press release - Regulatory

Targovax and Prof. Michael Uhlin at Karolinska Institutet enter research collaboration

January 12, 2022

Press release - Regulatory

Targovax ASA: Targovax awarded NOK 8.2m grant by Innovation Norway

IR contact

Dr Lubor Gaal

Chief Financial Officer

lubor.gaal@targovax.com

(+34) 683 343 811

Renate Birkeli

Investor Relations

renate.birkeli@targovax.com

(+47) 922 61 624

Q3 interim report 2022

Targovax ASA (OSE: TRVX) announced its third quarter 2022 results on Thursday 3 November 2022. Targovax’s management will present the results at a live streamed webcast at 10:00 am CET to investors, analysts and the press.

Read the report